Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.39 |
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608248 | 0.84 | APP (0.46) | APPRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL13127442 | 0.83 | IP6K1 (0.50) | RAB9ANPC1MAPTMAPK1CCNB2 | |
| SCHEMBL1608493 | 0.82 | APP (0.46) | APPRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL1608233 | 0.80 | APP (0.44) | APPRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL3795673 | 0.76 | IP6K1 (0.56) | APPRAB9ANPC1MAPTPOLB | |
| SCHEMBL31361978 | 0.76 | IP6K1 (0.56) | APPRAB9ANPC1MAPTPOLB | |
| SCHEMBL17283471 | 0.76 | QPCT (0.47) | APPRAB9ANPC1POLBQPCT | |
| SCHEMBL1608453 | 0.76 | APP (0.41) | APPRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL31063702 | 0.75 | APP (0.47) | APPRAB9ANPC1MAPTMAPK1 | |
| SCHEMBL1249681 | 0.75 | TNIK (0.55) | APPRAB9ANPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | claimed |
| EP-2285789-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | Merck Sharp & Dohme Corp. (US) | 2011-02-23 | — | — | EP | claimed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | claimed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | MERCK & CO. INC. | 2011-04-07 | — | — | US | disclosed |
| WO-2009146343-A1 | NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES | MERCK & CO., INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110081297-A1 | Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles | APP, PSEN1, BACE1 | APP 1/4885RAB9A 4026/4885NPC1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.